RFK Jr. Allows Sale of Six Peptide Drugs, Overruling FDA

On October 30, the U.S. Health Secretary Robert F. Kennedy Jr. issued a new rule allowing specialty pharmacies to sell six specific peptide drugs, overriding the Food and Drug Administration's (FDA) stance on the matter. The rule, titled 'Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances,' was published in the Federal Register.

Kennedy's decision permits compounding pharmacies to produce and sell these peptides in bulk, despite the FDA's removal of the substances from an approved list in 2023 due to safety concerns. The FDA had previously expressed that there is insufficient evidence to prove the peptides' effectiveness and potential dangers.

This new policy does not alter the regulatory status of the peptides but instructs the Department of Health and Human Services (HHS) to cease enforcement actions against pharmacies producing these drugs. The rule was quietly proposed earlier in October.

Kennedy, who is known for his anti-vaccine stance, is a prominent figure in the 'Make America Health Again' movement. Many influential members of this movement, including Kennedy himself, advocate for and sell these peptide drugs.

Critics have raised concerns about the potential conflicts of interest, as Kennedy's allies stand to benefit financially from the sale of these peptides. The FDA's scientists continue to warn about the lack of evidence supporting the peptides' efficacy and the potential risks they pose to public health.